Natural Products and Derivatives as Potential Zika virus Inhibitors: A Comprehensive Review
Viruses · 2023
DOI: 10.3390/v15051211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Rosângela Santos Pereira und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil. Hauptthemen laut MEDLINE: Zika Virus, Biological Products, Zika Virus Infection. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil, INCT-CNPq Program.
Abstract (Originalsprache)
Zika virus (ZIKV) is an arbovirus whose infection in humans can lead to severe outcomes. This article reviews studies reporting the anti-ZIKV activity of natural products (NPs) and derivatives published from 1997 to 2022, which were carried out with NPs obtained from plants (82.4%) or semisynthetic/synthetic derivatives, fungi (3.1%), bacteria (7.6%), animals (1.2%) and marine organisms (1.9%) along with miscellaneous compounds (3.8%). Classes of NPs reported to present anti-ZIKV activity include polyphenols, triterpenes, alkaloids, and steroids, among others. The highest values of the selectivity index, the ratio between cytotoxicity and antiviral activity (SI = CC50/EC50), were reported for epigallocatechin gallate (SI ≥ 25,000) and anisomycin (SI ≥ 11,900) obtained from Streptomyces bacteria, dolastane (SI = 1246) isolated from the marine seaweed Canistrocarpus cervicorni, and the flavonol myricetin (SI ≥ 862). NPs mostly act at the stages of viral adsorption and internalization in addition to presenting virucidal effect. The data demonstrate the potential of NPs for developing new anti-ZIKV agents and highlight the lack of studies addressing their molecular mechanisms of action and pre-clinical studies of efficacy and safety in animal models. To the best of our knowledge, none of the active compounds has been submitted to clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
- Department of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
- Department of Microbiology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
ORCID-Profile: Priscilla Rodrigues Valadares Campana, Mauro Martins Teixeira, Fernão Castro Braga
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil
- INCT-CNPq Program
Zitieren
APA
Pereira, R. S., Santos, F. C. P., Campana, P. R. V., Costa, V. V., de Pádua, R. M., Souza, D. G., Teixeira, M. M., & Braga, F. C. (2023). Natural Products and Derivatives as Potential Zika virus Inhibitors: A Comprehensive Review. Viruses. https://doi.org/10.3390/v15051211
Vancouver
Pereira RS, Santos FCP, Campana PRV, Costa VV, de Pádua RM, Souza DG, et al. Natural Products and Derivatives as Potential Zika virus Inhibitors: A Comprehensive Review. Viruses. 2023. doi:10.3390/v15051211
BibTeX
@article{Pereira2023,
author = {Pereira, Rosângela Santos and Santos, Françoise Camila Pereira and Campana, Priscilla Rodrigues Valadares and Costa, Vivian Vasconcelos and de Pádua, Rodrigo Maia and Souza, Daniele G and Teixeira, Mauro Martins and Braga, Fernão Castro},
title = {Natural Products and Derivatives as Potential Zika virus Inhibitors: A Comprehensive Review},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15051211}
}
EUVIMED